Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RLMD 
Relmada Therapeutics Inc (RLMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: RLMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1
1 Year Target Price $1
| 0 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.62% | Avg. Invested days 33 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 75.01M USD | Price to earnings Ratio - | 1Y Target Price 1 |
Price to earnings Ratio - | 1Y Target Price 1 | ||
Volume (30-day avg) 3 | Beta 0.92 | 52 Weeks Range 0.24 - 3.67 | Updated Date 11/1/2025 |
52 Weeks Range 0.24 - 3.67 | Updated Date 11/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.2 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.45 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -95.67% | Return on Equity (TTM) -175.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 67670173 | Price to Sales(TTM) - |
Enterprise Value 67670173 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.54 | Shares Outstanding 33191622 | Shares Floating 23007105 |
Shares Outstanding 33191622 | Shares Floating 23007105 | ||
Percent Insiders 18.85 | Percent Institutions 34.31 |
Upturn AI SWOT
Relmada Therapeutics Inc
Company Overview
History and Background
Relmada Therapeutics Inc. is a late-stage biotechnology company focused on developing and commercializing novel therapies for central nervous system (CNS) diseases, including depression, pain, and other neurological disorders. It was founded in 2004 and has evolved through various clinical trials and strategic shifts.
Core Business Areas
- Neurological Disorders: Focuses on developing therapies for CNS disorders, particularly pain management and depression.
Leadership and Structure
Relmada's leadership includes a CEO, CFO, CMO, and other key executives overseeing clinical development, regulatory affairs, and business operations. The company has a board of directors that provides strategic oversight.
Top Products and Market Share
Key Offerings
- REL-1017 (dextromethadone): A novel NMDA receptor channel blocker under development as an adjunctive treatment for major depressive disorder (MDD). Phase 3 clinical trials are complete. Market share is currently 0% as the drug is not yet approved. Competitors include SSRIs, SNRIs, and other novel antidepressants from companies like Axsome Therapeutics (AXSM) and Sage Therapeutics (SAGE).
Market Dynamics
Industry Overview
The pharmaceutical industry for CNS disorders is large and growing, with significant unmet needs in depression and pain management. Competition is intense, with many companies developing novel therapies.
Positioning
Relmada is positioned as a late-stage developer of novel CNS therapies, primarily focused on REL-1017 for MDD. Its competitive advantage lies in the potential for REL-1017 to offer a differentiated mechanism of action compared to existing antidepressants.
Total Addressable Market (TAM)
The MDD market is estimated to be worth billions of dollars annually. Relmada's positioning depends on the success of REL-1017 and its ability to capture a significant share of this market.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action for REL-1017
- Late-stage clinical development
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Dependence on a single key asset (REL-1017)
- High cash burn rate
- Regulatory risks associated with drug approval
- Limited commercial infrastructure
Opportunities
- Potential FDA approval and commercialization of REL-1017
- Expansion of pipeline through additional indications or acquisitions
- Partnerships with larger pharmaceutical companies
- Growing market for novel CNS therapies
Threats
- Failure of clinical trials or regulatory approval
- Competition from existing and emerging therapies
- Pricing and reimbursement pressures
- Generic erosion of existing products
Competitors and Market Share
Key Competitors
- AXSM
- SAGE
- LLY
- ABBV
Competitive Landscape
Relmada's competitive advantage lies in its novel mechanism of action, but it faces significant competition from larger pharmaceutical companies with established CNS portfolios and commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Relmada's historical growth has been driven by clinical trial progress and investor sentiment. Revenue is not significant currently.
Future Projections: Future growth is heavily dependent on the successful approval and commercialization of REL-1017. Analyst projections vary based on the likelihood of success.
Recent Initiatives: Recent initiatives include completing Phase 3 trials for REL-1017 and preparing for potential FDA submission.
Summary
Relmada Therapeutics is a high-risk, high-reward biotechnology company focused on developing novel therapies for CNS disorders. Its success hinges on the approval and commercialization of REL-1017. The company faces significant competition and financial risks, but the potential market for effective treatments for depression is substantial.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on thorough due diligence and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Relmada Therapeutics Inc
Exchange NASDAQ | Headquaters Coral Gables, FL, United States | ||
IPO Launch date 2014-10-09 | CEO & Director Dr. Sergio Traversa M.B.A., Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.relmada.com |
Full time employees 17 | Website https://www.relmada.com | ||
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.